Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Lasers Surg Med ; 49(10): 882-885, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28881431

RESUMO

OBJECTIVES: The purpose of this study is to assess patient's satisfaction treatment outcomes and out-of-pocket expense for the fractional CO2 laser (SmartXide) in the treatment of genitourinary symptoms of menopause (GSM). MATERIALS AND METHODS: A multicenter retrospective cohort study of patients who completed a course of three vaginal treatments with the SmartXide11 Fractional CO2 laser. Patients contacted via telephone and asked to participate in questionnaires to evaluate for adverse outcomes since last treatment, symptom severity before and after treatment, patient satisfaction with treatment, patient satisfaction with out-of-pocket expense, and sexual function. RESULTS: Of the 368 patients contacted, 122 agreed to be interviewed. No patients reported seeking emergent medical treatment. Patient reported vaginal dryness significantly improved following treatment (P < 0.05). The frequency of intercourse increased from "once a month" to "few times a month" (P < 0.001). The vast majority of patients reported being satisfied with their treatment results (86%) and with the cost of treatment (78%). Satisfaction with the out-of-pocket expense did not correlate with household income (P = 0.07). CONCLUSION: The SmartXide Fractional CO2 laser is a safe and efficacious treatment for GSM. This treatment is associated with a high level of patient satisfaction with both treatment results and out-of-pocket expense. Lasers Surg. Med. 49:882-885, 2017. © 2017 Wiley Periodicals, Inc.


Assuntos
Dispareunia/cirurgia , Gastos em Saúde , Lasers de Gás/uso terapêutico , Menopausa , Vagina/cirurgia , Doenças Vaginais/cirurgia , Idoso , Dispareunia/economia , Feminino , Pesquisas sobre Atenção à Saúde , Humanos , Pessoa de Meia-Idade , Satisfação do Paciente , Estudos Retrospectivos , Síndrome , Resultado do Tratamento , Estados Unidos , Doenças Vaginais/economia
2.
Curr Med Res Opin ; 25(11): 2689-98, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19775194

RESUMO

OBJECTIVE: There is currently a gap in treatment options for menopausal symptoms and a need for comprehensive therapies that are safe and effective for postmenopausal women. This review discusses challenges in the management of menopausal symptoms and the effect of the Women's Health Initiative (WHI) study findings on current treatment patterns. It also examines present and future therapies. RESEARCH DESIGN AND METHODS: A literature search was conducted using Medline, the Cochrane Database, and the National Heart Lung and Blood Institute WHI website with the following search terms: primary care, menopause, vasomotor symptoms, hormone therapy, osteoporosis, and vaginal atrophy. Searches were limited to articles published between 1995 and 2009. RESULTS: Comprehensive therapies that target several aspects of menopause, such as vasomotor symptoms and chronic disease prevention, are currently hormone based. These hormone-based approaches are considered more effective than currently available nonhormonal therapies for the relief of menopausal symptoms. However, hormone therapy is not recommended for women at high risk for venous thromboembolic events, cardiovascular disease, and/or breast cancer. A need exists for novel therapies that mitigate menopausal symptoms, provide protection from osteoporosis, and encourage patient compliance without promoting cancer, heart disease, or stroke. Emerging modalities and strategies, such as the tissue selective estrogen complex (TSEC), Org 50081, MF101, and desvenlafaxine, may provide improved options for postmenopausal women. CONCLUSIONS: Several new menopausal therapies that may help to address the ongoing unmet need for safe and effective therapies for postmenopausal women are currently in development. In particular, the TSEC, which provides the benefits of both a selective estrogen receptor modulator and conjugated estrogens with an improved tolerability profile, may offer advantages over currently available treatment options. Limitations of this review include the narrow search criteria and limited search period.


Assuntos
Assistência Integral à Saúde , Menopausa/fisiologia , Atitude Frente a Saúde , Sintomas Comportamentais/economia , Sintomas Comportamentais/terapia , Assistência Integral à Saúde/economia , Efeitos Psicossociais da Doença , Terapia de Reposição de Estrogênios/economia , Terapia de Reposição de Estrogênios/estatística & dados numéricos , Feminino , Humanos , Menopausa/psicologia , Osteoporose Pós-Menopausa/economia , Osteoporose Pós-Menopausa/terapia , Qualidade da Assistência à Saúde , Qualidade de Vida , Doenças Vaginais/economia , Doenças Vaginais/etiologia , Doenças Vaginais/terapia , Sistema Vasomotor/fisiologia
4.
DST j. bras. doenças sex. transm ; 15(1): 4-15, 2003. tab, graf
Artigo em Português | LILACS | ID: lil-345583

RESUMO

Apesar do corrimento vaginal ser uma das mais antigas e frequentes afecçöes que acometem a saúde física e emocional da mulher, do diagnóstico laboratorial ser relativamente fácil e de baixo custo, das recidivas e reinfecçöes serem constantes, ainda na atualidade, sua abordagem é feita de maneira simplista e empírica, tanto para o diagóstico como para a terapêutica. Este estudo objetiva enfatizar a importåncia de uma abordagem holística no atendimento à mulher com corrimento vaginal, pois acreditamos que tal afecçäo, suas recidivas e reinfecçöes näo estäo exclusivamente associadas a infectividade e virulência do patógeno envolvido, mas também ao contexto socioeconömico e cultural em que a mulher está inserida


Assuntos
Humanos , Feminino , Adulto , Infecções Sexualmente Transmissíveis/economia , Doenças Vaginais/diagnóstico , Doenças Vaginais/economia , Doenças Vaginais/etiologia , Fatores Socioeconômicos , Saúde da Mulher
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA